SEC Form 4
Acadia Pharmaceuticals Inc. (ACAD) insider trading
In the 12 months to Oct 24, 2026, 3 ACAD insiders reported open-market sales of $1.7M across 4 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $1.7M
- 4 filings · 3 insiders
- Open-market purchases
- $0
- 0 filings
- Pre-arranged sales (10b5-1)
- 2 of 4
- $885.2K of $1.7M sold (53%)
Who traded ACAD, and when
- Sale
- Sale, pre-arranged (10b5-1)
ACAD daily close from Oct 24, 2025 to Oct 23, 2026, between $18.62 and $30.57, last $19.73. 4 sale and 0 purchase filings by 3 insiders, marked at their filing dates. James M. Daly, Director: sold $671.0K across 1 filing, first filed Nov 12, 2025, last Nov 12, 2025. Mark C. Schneyer, EVP, CHIEF FINANCIAL OFFICER: sold $587.2K across 1 filing, first filed Aug 7, 2026, last Aug 7, 2026. James Kihara, PRINCIPAL ACCOUNTING OFFICER: sold $412.3K across 2 filings, first filed May 27, 2026, last Jun 29, 2026.
Largest mark · tap a row for others
James M. Daly · Director
Sale $670,983
30,000 shares at $22.37 avg
Filed Nov 12, 2025 · traded Nov 10
Close on filing date $24.13
James M. Daly · Director
Director
$671.0K soldMark C. Schneyer · EVP, CHIEF FINANCIAL OFFICER
EVP, CHIEF FINANCIAL OFFICER
$587.2K soldJames Kihara · PRINCIPAL ACCOUNTING OFFICER
PRINCIPAL ACCOUNTING OFFICER
$412.3K soldHas Acadia Pharmaceuticals Inc.'s CEO sold stock?
No. Adams Catherine Owen (CEO) made no open-market sales filed as CEO in the last 12 months.
Open-market trades
4 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| James M. Daly | Director | $671.0K | — | 1 | — | |
| Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | $587.2K | — | 1 | 100% of sales | |
| James Kihara | PRINCIPAL ACCOUNTING OFFICER | $412.3K | — | 2 | 72% of sales |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | SalePre-arranged (10b5-1) | 20,141 | $29.16 | $587.2K | 67,828 | |
traded | James Kihara PRINCIPAL ACCOUNTING OFFICER | SalePre-arranged (10b5-1) | 11,421 | $26.08 | $297.9K | 13,088 | |
traded | James Kihara PRINCIPAL ACCOUNTING OFFICER | Sale | 5,401 | $21.18 | $114.4K | 24,509 | |
traded | James M. Daly Director | Sale | 30,000 | $22.37 | $671.0K | 4,041 |
GET /stocks/filings/vX/form-4?tickers=ACAD&filing_date.gte=2025-10-24&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"ACAD"
],
"issuer_cik": "0001070494",
"owner_cik": "0001899977",
"accession_number": "0001899977-26-000008",
"form_type": "4",
"filing_date": "2026-08-07",
"period_of_report": "2026-08-05",
"issuer_name": "ACADIA PHARMACEUTICALS INC",
"issuer_trading_symbol": "ACAD",
"owner_name": "Schneyer Mark C.",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "EVP, CHIEF FINANCIAL OFFICER",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-08-05",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 5849,
"transaction_price_per_share": 29.0029,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 67828,
"transaction_value": 169637.9621,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F2",
"description": "Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 19, 2025."
},
{
"id": "F3",
"description": "The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."
}
]
},
{
"tickers": [
"ACAD"
],
"issuer_cik": "0001070494",
"owner_cik": "0001899977",
"accession_number": "0001899977-26-000008",
"form_type": "4",
"filing_date": "2026-08-07",
"period_of_report": "2026-08-05",
"issuer_name": "ACADIA PHARMACEUTICALS INC",
"issuer_trading_symbol": "ACAD",
"owner_name": "Schneyer Mark C.",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "EVP, CHIEF FINANCIAL OFFICER",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-08-06",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 5000,
"transaction_price_per_share": 29,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 77120,
"transaction_value": 145000,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F2",
"description": "Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 19, 2025."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 45 records
- Option exercises25 records
- Tax withholding (sold to cover)18 records
- Grants and awards2 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
Build this yourself
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for ACAD every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.